论文部分内容阅读
目的 为评价国产降纤酶对急性脑梗死的治疗效果及安全性。 方法 以低分子右旋糖酐、钙离子拮抗剂、银杏制剂为对照药 ,从 1 998年 1月至 1 999年 1月共观察脑梗死急性期脑梗死 (发病 7天内 )病人 30例 ,对照组 1 4例。 结果 用降纤酶治疗脑梗死第 1天 ,临床症状即出现明显改善 ,其疗效在治疗后第 1天、第 7天、第 1 4天均明显优于对照组。 结论 认为降纤酶治疗急性脑梗死疗效是肯定的。从实验室检查发现 ,降纤酶可明显降低纤维蛋白原 ,并使凝血酶原时间延长 ,这与以往研究结果完全一致 ,表明降纤酶是通过降低纤维蛋白原而改善临床症状的。本组研究资料提示 ,降纤酶可降低血浆中纤维蛋白原 ,对急性脑梗死有明显疗效 ,未发现有明显副作用。因此 ,我们认为在有凝血指标监护下使用降纤酶治疗急性脑梗死是安全有效的 ,值得在临床上进一步推广。
Objective To evaluate the therapeutic effect and safety of domestic defibrase on acute cerebral infarction. Methods From January 1998 to January 1999, 30 cases of acute cerebral infarction (within 7 days of onset) of cerebral infarction were observed with low molecular dextran, calcium ion antagonist and ginkgo preparations as controls. The control group was 14 example. Results With defibrase treatment of cerebral infarction on the first day, clinical symptoms showed significant improvement, the efficacy of the first day after treatment, the first 7 days, 14 days were significantly better than the control group. Conclusions that defibrase in the treatment of acute cerebral infarction is positive. From the laboratory examination found that defibrase can significantly reduce fibrinogen, prothrombin time and prolongation, which is consistent with previous findings, indicating that defibrase by reducing fibrinogen and improve clinical symptoms. This group of research data suggest that defibrase can reduce plasma fibrinogen, acute cerebral infarction significant effect, no significant side effects were not found. Therefore, we believe that the use of defibrase in the monitoring of coagulation indicators in the treatment of acute cerebral infarction is safe and effective, it is worth further promotion in the clinical.